Literature DB >> 8541534

CD34+ endothelial cell lines derived from murine yolk sac induce the proliferation and differentiation of yolk sac CD34+ hematopoietic progenitors.

C Fennie1, J Cheng, D Dowbenko, P Young, L A Lasky.   

Abstract

Embryonic hematopoiesis is initiated in part in the blood islands of the yolk sac. Previous confocal microscopic analysis has shown that the CD34 antigen, a mucin-like cell surface glycoprotein that is expressed by hematopoietic progenitors and all endothelial cells of the adult and embryo, is also found on a subset of luminal hematopoietic-like cells in the yolk sac blood islands as well as on the vascular endothelium lining these early hematopoietic locations. We show here that, as in all other hematopoietic sites thus far examined, immunoaffinity-purified CD34+ nonadherent cells from murine yolk sacs contain the vast majority of erythroid and myeloid progenitor cell colony forming activity. To examine the developmental interactions between these CD34+ hematopoietic progenitor cells of the yolk sac and the CD34+ yolk sac endothelium, we have immunaffinity-purified adherent endothelial cells from day 10.5 yolk sacs using CD34 antiserum and produced cell lines by transformation with a retrovirus expressing the polyoma middle T antigen. Analysis of these cell lines for CD34, von Willebrand's factor, FLK 1 and FLT 1 expression, and capillary growth in Matrigel indicates that they appear to be endothelial cells, consistent with their original phenotype in vivo. Coculture of yolk sac CD34+ hematopoietic cells on these endothelial cell lines results in up to a 60-fold increase in total hematopoietic cell number after approximately 8 days. Analysis of these expanded hematopoietic cells showed that the majority were of the monocyte/macrophage lineage. In addition, examination of the cultures showed the rapid formation of numerous cobblestone areas, a previously described morphologic entity thought to be representative of early pluripotential stem cells. Scrutiny of the ability of these endothelial cell lines to expand committed progenitor cells showed up to a sixfold increase in erythroid and myeloid colony-forming cells after 3 to 6 days in culture, consistent with the notion that these embryonic endothelial cells mediate the expansion of these precursor cells. Polymerase chain reaction analyses showed that most of the cell lines produce FLK-2/FLT-3 ligand, stem cell factor, macrophage colony-stimulating factor, leukemia-inhibitory factor, and interleukin-6 (IL-6), whereas there is a generally low or not measurable production of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, IL-1, IL-3, transforming growth factor beta-1, erythropoietin, or thrombopoietin. The output of mature hematopoietic cells from these cocultures can be modified to include an erythroid population by the addition of exogenous erythropoietin. These data suggest that endothelial cell lines derived form the yolk sac provide an appropriate hematopoietic environment for the expansion and differentiation of yolk sac progenitor cells into at least the myeloid and erythroid lineages.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8541534

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  CD34-positive stem cells: in the treatment of heart and vascular disease in human beings.

Authors:  Alexander R Mackie; Douglas W Losordo
Journal:  Tex Heart Inst J       Date:  2011

2.  EKLF and KLF2 have compensatory roles in embryonic beta-globin gene expression and primitive erythropoiesis.

Authors:  Priyadarshi Basu; Tina K Lung; Wafaa Lemsaddek; Thanh Giang Sargent; David C Williams; Mohua Basu; Latasha C Redmond; Jerry B Lingrel; Jack L Haar; Joyce A Lloyd
Journal:  Blood       Date:  2007-08-03       Impact factor: 22.113

Review 3.  Beyond mere markers: functions for CD34 family of sialomucins in hematopoiesis.

Authors:  Sebastian George Barton Furness; Kelly McNagny
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  In vitro and in vivo differentiation into B cells, T cells, and myeloid cells of primitive yolk sac hematopoietic precursor cells expanded > 100-fold by coculture with a clonal yolk sac endothelial cell line.

Authors:  L S Lu; S J Wang; R Auerbach
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

Review 5.  Experimental approaches to derive CD34+ progenitors from human and nonhuman primate embryonic stem cells.

Authors:  Qiang Shi; John L VandeBerg
Journal:  Am J Stem Cells       Date:  2015-03-15

6.  Primitive lymphohematopoietic precursor cell lines generated in culture from day 7 early-mid-primitive streak stage mouse embryo.

Authors:  R Palacios; B A Imhof
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

7.  Leukemogenesis caused by incapacitated GATA-1 function.

Authors:  Ritsuko Shimizu; Takashi Kuroha; Osamu Ohneda; Xiaoqing Pan; Kinuko Ohneda; Satoru Takahashi; Sjaak Philipsen; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

8.  Human embryonic stem cell-derived vascular progenitor cells capable of endothelial and smooth muscle cell function.

Authors:  Katherine L Hill; Petra Obrtlikova; Diego F Alvarez; Judy A King; Susan A Keirstead; Jeremy R Allred; Dan S Kaufman
Journal:  Exp Hematol       Date:  2010-01-11       Impact factor: 3.084

9.  Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration.

Authors:  Zhuqing Qu-Petersen; Bridget Deasy; Ron Jankowski; Makato Ikezawa; James Cummins; Ryan Pruchnic; John Mytinger; Baohong Cao; Charley Gates; Anton Wernig; Johnny Huard
Journal:  J Cell Biol       Date:  2002-05-20       Impact factor: 10.539

10.  Zinc finger protein, Hzf, is required for megakaryocyte development and hemostasis.

Authors:  Yuki Kimura; Adam Hart; Masanori Hirashima; Chen Wang; Doug Holmyard; Jackie Pittman; Xin-Li Pang; Carl W Jackson; Alan Bernstein
Journal:  J Exp Med       Date:  2002-04-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.